



.

6369355

* ****

1.000

225

MICROCOPY RESOLUTION TEST CHART NATIONAL BUREAU OF STANDARDS-1963-A

MANAGEMENT OF HARD TISSUE AVULSIVE WOUNDS AND MANAGEMENT OF OROFACIAL FRACTURES

ANNUAL REPORT

Larry G. McCoy and Craig R. Hassler

July 15, 1977

Supported by

U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND Fort Detrick, Frederick, Maryland 21701-5012

Contract No. DADA17-69-C-9118

BATTELLE Columbus Laboratories 505 King Avenue Columbus, Ohio 43201

DOD DISTRIBUTION STATEMENT



The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.



080

85 8 9

MANAGEMENT OF HARD TISSUE AVULSIVE WOUNDS AND MANAGEMENT OF OROFACIAL FRACTURES

AD

ANNUAL REPORT

Larry G. McCoy and Craig R. Hassler

July 15, 1977

Supported by

U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND Fort Detrick, Frederick, Maryland 21701-5012

Contract No. DADA17-69-C-9118

BATTELLE Columbus Laboratories 505 King Avenue Columbus, Ohio 43201

DOD DISTRIBUTION STATEMENT

Approved for public release; distribution unlimited.

The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.

| REPORT HUMBER 2. GOVY ACCESSION NO 3. RECIN Management of Hard Tissue Avulsive Mounds and Management of Orofacial Fractures 5. TYPE C Author(a) 8. CONTR Management of Orofacial Fractures 9. CONTR Author(a) 9. CONTR McCoy, L. G. and Hassler, C. R. DADA1 PERFORMING ORGANIZATION NAME AND ADDRESS 10. PROGLEMENT Battelle Columbus Laboratories 505 King Avenue Columbus, Ohio 43201 62775A ControlLing OFFICE NAME AND ADDRESS 12. REFO U.S. Army Medical Research and Development July 11 Command Fort Detrick, Frederick, Maryland 21701-5012 15. SECUI MONITORING AGENCY NAME & ADDRESS(II different from Controlling Office) 16. SECUI Uncla 15. DESTRIBUTION STATEMENT (of the abstract entered in Black 20, If different from Report) Approved for public release; distribution unlimited. 7. DISTRIBUTION STATEMENT (of the abstract entered in Black 20, If different from Report) Bioceramics Maxillofacial Tric Ceramics Maxillofacial Tric Prosthetic Materials Biodegradable Ceramics Calc Prosthetic Materials Bioresorable Ceramics Calc | ENT'S CATALOG NUMBER F REPORT & PERIOD COVERED 1 Report 1, 1976-Aug. 15, 19 WMING ORG. REPORT NUMBER |
|---|--|
| TITLE (and Subtitio) S. TYPEC Management of Hard Tissue Avulsive Wounds and Management of Orofacial Fractures S. TYPEC AuthoR(a) S. TYPEC AuthoR(a) S. TYPEC AUTHOR(a) S. TYPEC MCCOY, L. G. and Hassler, C. R. DADAI PERFORMING ORGANIZATION NAME AND ADDRESS Io. PROGRAMING ORGANIZATION NAME AND ADDRESS Battelle Columbus Laboratories 505 King Avenue Columbus, Ohio 43201 G2775A. I. CONTROLLING OFFICE NAME AND ADDRESS Iii. Reformed U.S. Army Medical Research and Development July 1 Command Fort Detrick, Frederick, Maryland 21701-5012 Is secure MONITORING AGENCY NAME & ADDRESS(II different free Controlling Office) Is. Secure MONITORING AGENCY NAME & ADDRESS(II different free Report) Is. Secure Approved for public release; distribution unlimited. Is. Description DISTRIBUTION STATEMENT (of the obstrect entered in Block 20, If different free Report) Bioceramics Maxillofacial Tric Ceramics Maxillofacial Tric Ceramics Maxillofacial Tric Prosthetic Materials Biodegradable Ceramics Calc | F REPORT & PERIOD COVERED 1 Report 1, 1976-Aug. 15, 19 WING ORG. REPORT NUMBER |
| TITLE (and Subdits) B. TYPE (and Subdits) Management of Hard Tissue Avulsive Wounds and Management of Orofacial Fractures Annua April Author(s) Contractures Author(s) Contractures Author(s) Contractures PERFORMING ORGANIZATION NAME AND ADDRESS Contractures Battelle Columbus Laboratories 505 King Avenue Columbus, Ohio 43201 62775A Controlling OFFICE NAME AND ADDRESS 12. REFO U.S. Army Medical Research and Development Command 13. Mumil Fort Detrick, Frederick, Maryland 21701-5012 15. MONITORING AGENCY NAME & ADDRESS(If different free Controlling Office) 15. SECULUR MONITORING AGENCY NAME & ADDRESS(If different free Controlling Office) 15. SECULUR MONITORING AGENCY NAME & ADDRESS(If different free Controlling Office) 15. SECULUR Approved for public release; distribution unlimited. 18. SUPPLEMENTARY NOTES Statement (of the obstreet entered in Block 20, If different free Report) 19. Seculation of Call Monitoring Inplants Avuisive Wounds Calc Prosthetic Materials Biodegradable Ceramics Calc Inplant Materials Biodegradable Ceramics Calc | REPORT & PERIOD COVEREN 1 Report 1, 1976-Aug. 15, 19 MING ORG. REPORT NUMBER |
| Management of Hard Tissue Avulsive Wounds and Management of Orofacial Fractures April 9. PERFORMING ORGANIZATION NAME AND ADDRESS AUTHOR(a) 8. CONTR MCCoy, L. G. and Hassler, C. R. 9. CONTR DADA1 PERFORMING ORGANIZATION NAME AND ADDRESS 10. PROG AREA Sols King Avenue Columbus, Ohio 43201 10. PROG AREA I. CONTROLLING OFFICE NAME AND ADDRESS 12. REFORMENT (Command Fort Detrick, Frederick, Maryland 21701-5012 4. MONITORING AGENCY NAME & ADDRESS(II different from Controlling Office) 15. SECUTURING 15. SECUTURING TO PUBLIC release; distribution unlimited. 4. DISTRIBUTION STATEMENT (of the Report) Approved for public release; distribution unlimited. 7. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, If different from Report) Bioceramics Maxillofacial 5. SUPPLEMENTARY NOTES 5. SUPPLEMENTARY NOTES 5. SUPPLEMENTARY NOTES 5. SUPPLEMENTARY NOTES 5. AREY WORDS (Continue on reverse side If necessary and identify by block number) Bioceramics Maxillofacial Tric Caramic Inplants 6. SUPPLEMENTARY NOTES Scale Biodegradable Ceramics Calc Calc Prosthetic Materials Biodegradable Ceramics 6. ABSTRACT (Continue on reverse oth H messary and Identify by block number) (n Encore Main Contaction of the second processory and Identify by block number) | 1, 1976-Aug. 15, 19 MING ORG. REPORT NUMBER |
| Management of Orofacial Fractures April AuthoR(a) 6. PERFO AuthoR(a) 6. Contremation NAME AND ADDRESS Battelle Columbus Laboratories 0. PROG SO5 King Avenue 62775A Columbus, Ohio 43201 62775A 1. CONTROLLING OFFICE NAME AND ADDRESS 12. REFO U.S. Army Medical Research and Development July 1 Columbus, Ohio 43201 13. Nume 1. CONTROLLING OFFICE NAME & ADDRESS 14. REFO U.S. Army Medical Research and Development July 1 Command Fort Detrick, Frederick, Maryland 21701-5012 15. SECU 4. MONITORING AGENCY NAME & ADDRESS(If different from Controlling Office) 18. SECU 4. MONITORING AGENCY NAME & ADDRESS(If different from Controlling Office) 18. SECU 4. MONITORING AGENCY NAME & ADDRESS(If different from Report) Approved for public release; distribution unlimited. 7. DISTRIBUTION STATEMENT (of the obstract entered in Block 20, if different from Report) Bioceramics 8. SUPPLEMENTARY HOTES Maxillofacial Tric 8. SUPPLEMENTARY HOTES Calc Distribution con reverse side if necessary and identify by block number) Tric Bioceramics Maxillofacial Tric | I, 1970-AUG. 15, 19 RMING ORG. REPORT NUMBER |
| AUTHOR(w) AUTHOR(w) McCoy, L. G. and Hassler, C. R. DADA1 PERFORMING ORGANIZATION NAME AND ADDRESS Battelle Columbus Laboratories 505 King Avenue Columbus, Ohio 43201 ControlLing OFFICE NAME AND ADDRESS U.S. Army Medical Research and Development Command Fort Detrick, Frederick, Maryland 21701-5012 15 MONITORING AGENCY NAME & ADDRESS(If different from Controlling Office) Is. SECUI Uncla Is. DECC SCHE DISTRIBUTION STATEMENT (of this Report) Approved for public release; distribution unlimited. DISTRIBUTION STATEMENT (of the obstract entered in Block 20, If different from Report) Bioceramics Maxillofacial Tric Ceramic Implants Avulsive Mounds Calc Prosthetic Materials Biodegradable Ceramics Implant Materials Biorescape well Meeting theoremeters (A EXTRACT (Condume on reverse other M meetings) In force armics Implant Materials Biorescape well Meetings | AMINU UNG. REFURI RUMBER |
| AUTHOR(a) MCCOY, L. G. and Hassler, C. R. MCCOY, L. G. and Hassler, C. R. DADA1 DADA1 PERFORMING ORGANIZATION NAME AND ADDRESS Battelle Columbus Laboratories SO5 King Avenue Columbus, Ohio 43201 Controlling OFFICE NAME AND ADDRESS U.S. Army Medical Research and Development Command Fort Detrick, Frederick, Maryland 21701-5012 Is rot Detrick, Frederick, Maryland 21701-5012 Is SECUI Uncla Is. SECUI SOFTRIBUTION STATEMENT (of the obstreet enforced in Block 20, If different from Report) Approved for public release; distribution unlimited. SUPPLEMENTARY NOTES KEY WORDS (Continue on reverse side If necessary and Identify by block number) Bioceramics Maxillofacial Tric Ceramic Implants Avulsive Wounds Calc Prosthetic Materials Biodegradable Ceramics Implant Materials Biodegradable Ceramics Implant Materials Bioresorable Ceramics ABETRACT (Condumus and reverse of M Intervent and Identify by block number) // E/0727 MICS | |
| McCoy, L. G. and Hassler, C. R. DADA1 PERFORMING ORGANIZATION NAME AND ADDRESS 10. PROG NECOLIMA OFFICE NAME AND ADDRESS 10. PROG NECOLIMA OFFICE NAME AND ADDRESS 10. PROG NECOLIMA OFFICE NAME AND ADDRESS 12. REFORMATION U.S. Army Medical Research and Development Command 62775A Fort Detrick, Frederick, Maryland 21701-5012 15. NUMBER 15. NUMBER 15. SECUL Uncla 16. SECUL Uncla A MONITORING AGENCY NAME & ADDRESS(II different from Controlling Office) 18. SECUL Uncla 18. SECUL Uncla A. MONITORING AGENCY NAME & ADDRESS(II different from Controlling Office) 18. SECUL Uncla B. DISTRIBUTION STATEMENT (of the Report) 18. SECUL Approved for public release; distribution unlimited. 7. DISTRIBUTION STATEMENT (of the edetrect entered in Block 20, If different from Report) B. SUPPLEMENTARY NOTES Maxillofacial Tric Ceramics Maxillofacial Forous Ceramics Calc Biomaterials Porous Ceramics Calc Prosthetic Materials Biodegradable Ceramics Implant Materials Biodegradable Ceramics C. ABSTRACT (Continue on reverse of the Minesery of Identify by block number) // Fice CER Miccs | ACT OR GRANT NUMBER(+) |
| PERFORMING ORGANIZATION NAME AND ADDRESS Battelle Columbus Laboratories 505 King Avenue Columbus, Ohio 43201 CONTROLLING OFFICE NAME AND ADDRESS U.S. Army Medical Research and Development Command Fort Detrick, Frederick, Maryland 21701-5012 MONITORING AGENCY NAME & ADDRESS(If different from Controlling Office) Uncla To the statement (of the Report) Approved for public release; distribution unlimited. OISTRIBUTION STATEMENT (of the edetrect entered in Block 20, if different from Report) Bioceramics Maxillofacial Tric Geramics Maxillofacial Tric Ceramic Implants Avulsive Wounds Calc Prosthetic Materials Biodegradable Ceramics Implant Materials Biodegradable Ceramics ABSTRACT (Continue on reverse of the Macessenty of Identify by block number) // FlockerR Marcs | 7-69-C-9118 |
| PERFORMING ORGANIZATION NAME AND ADDRESS Battelle Columbus Laboratories 505 King Avenue Columbus, Ohio 43201 ControlLing OFFICE NAME AND ADDRESS U.S. Army Medical Research and Development Command Fort Detrick, Frederick, Maryland 21701-5012 MONITORING AGENCY NAME & ADDRESS(If different from Controlling Office) S. SECUIU Distribution STATEMENT (of the abstract entered in Block 20, If different from Report) Approved for public release; distribution unlimited. SUPPLEMENTARY NOTES KEY WORDS (Continue on reverse olds If necessary and identify by block number) Bioceramics Maxillofacial Tric Ceramic Implants Avuisive Mounds Calc Biomaterials Porous Ceramics Implant Materials Biodegradable Ceramics ABSTRACT (Caudame on reverse olds M measury of Identify by Ident mamber) // FiocerAMICS | |
| AREA Battelle Columbus Laboratories 505 King Avenue Columbus, Ohio 43201 Controlling office NAME AND ADDRESS U.S. Army Medical Research and Development Command Fort Detrick, Frederick, Maryland 21701-5012 U.S. Army Medical Research and Development Command Fort Detrick, Frederick, Maryland 21701-5012 U.S. MONITORING AGENCY NAME & ADDRESS(If different from Controlling Office) U.S. Army Medical Research and Development Command Fort Detrick, Frederick, Maryland 21701-5012 Uncla Tort Detrick, Frederick, Maryland 21701-5012 Uncla Tort Detrick of the ADDRESS(If different from Controlling Office) Uncla Tortstillution STATEMENT (of the electroct entered in Block 20, if different from Report) Approved for public release; distribution unlimited. SupplementArry NOTES KEY WORDS (Continue on reverse side if necessary and identify by block number) Bioceramics Maxillofacial Tric Ceramic Implants Avulsive Wounds Calc Biomaterials Porous Ceramics Calc Prosthetic Materials Biodegradable Ceramics Implant Materials Bioresorable Ceramics ABSTRACT (Cantinue on reverse other M recessary and Identify by block number) // Frocers mices | AM ELEMENT PROJECT TASK |
| SO5 King Avenue Columbus, Ohio 43201 G2775A G275A | E WORK UNIT NUMBERS |
| Columbus, Ohio 43201 1. CONTROLLING OFFICE NAME AND ADDRESS 12. REFO. U.S. Army Medical Research and Development July 1 Command Fort Detrick, Frederick, Maryland 21701-5012 15. MUMB Fort Detrick, Frederick, Maryland 21701-5012 16. MONITORING AGENCY NAME & ADDRESS(II different from Controlling Office) Is. succur 17. MONITORING AGENCY NAME & ADDRESS(II different from Controlling Office) Is. succur 18. DISTRIBUTION STATEMENT (of the Report) Approved for public release; distribution unlimited. 7. DISTRIBUTION STATEMENT (of the obstract entered in Block 20, II different from Report) 8. SUPPLEMENTARY NOTES 8. ADSTRACT (Continue on reverse olds If necessary and Identify by block number) Bioceramics Maxillofacial Tric Ceramics Ceramics Maxillofacial Prosthetic Materials Biodegradable Ceramics Implant Materials Bioresorable Ceramics Mattribut Fill Security of block number) In Columnation Fill Security of block number) < | 381627754825 44 044 |
| 1. CONTROLLING OFFICE NAME AND ADDRESS 12. REPOINT U.S. Army Medical Research and Development July 11 1. Command Fort Detrick, Frederick, Maryland 21701-5012 15. SECUING AGENCY NAME & ADDRESS(If different from Controlling Office) 15. SECUING AGENCY NAME & ADDRESS(If different from Controlling Office) 4. MONITORING AGENCY NAME & ADDRESS(If different from Controlling Office) 15. SECUING Control of the ADDRESS(If different from Controlling Office) 15. SECUING AGENCY NAME & ADDRESS(If different from Controlling Office) 4. MONITORING AGENCY NAME & ADDRESS(If different from Controlling Office) 15. SECUING CONTROL OF THE ADDRESS (If different from Controlling Office) 5. DISTRIBUTION STATEMENT (of the ebstrect entered in Block 20, If different from Report) 15. SECUING Continue on reverse elde If necessary and identify by block number) 6. SUPPLEMENTARY NOTES 11. Secure of the ebstrect entered in Block 20, If different from Report) 8. SUPPLEMENTARY NOTES 11. Secure of the ebstrect entered in Block 20, If different from Report) 8. SUPPLEMENTARY NOTES 11. Secure of the ebstrect entered in Block 20, If different from Report) 8. SUPPLEMENTARY NOTES 11. Secure of the ebstrect entered in Block 20, If different from Report) 9. KEY WORDS (Continue on reverse elde If necessary and identify by block number) 11. Secure of the ebstrect entered in Block 20, If different from Report) 9. KEY WORDS (Continue on reverse elde If necessary and identify by block number)< | JILLEN JROEJ. RR. UTT |
| U.S. Army Medical Research and Development Command Fort Detrick, Frederick, Maryland 21701-5012 July 14 Fort Detrick, Frederick, Maryland 21701-5012 15. SECUI 4. MONITORING AGENCY NAME & ADDRESS(If different free Controlling Office) 15. SECUI 4. MONITORING AGENCY NAME & ADDRESS(If different free Controlling Office) 15. SECUI 4. MONITORING AGENCY NAME & ADDRESS(If different free Controlling Office) 15. SECUI 4. MONITORING AGENCY NAME & ADDRESS(If different free Controlling Office) 15. SECUI 4. DISTRIBUTION STATEMENT (of the Report) Approved for public release; distribution unlimited. 7. DISTRIBUTION STATEMENT (of the obstract entered in Block 20, If different free Report) 8. SUPPLEMENTARY NOTES 8. SUPPLEMENTARY NOTES 9. KEY WORDS (Continue on reverse edde If necessary and identify by block number) Bioceramics Maxillofacial Tric Ceramic Implants Avulsive Wounds Calc Biomaterials Bioresorable Ceramics Calc Prosthetic Materials Bioresorable Ceramics Implant Materials Bioresorable Ceramics AMETRACT (Continue on reverse oth H researce on the H researce of the H r | IT DATE |
| LOMMAND Fort Detrick, Frederick, Maryland 21701-5012 4. MONITORING AGENCY NAME & ADDRESS(If different from Controlling Office) 4. MONITORING AGENCY NAME & ADDRESS(If different from Controlling Office) 4. MONITORING AGENCY NAME & ADDRESS(If different from Controlling Office) 5. SECUI 5. DISTRIBUTION STATEMENT (of the Report) Approved for public release; distribution unlimited. 7. DISTRIBUTION STATEMENT (of the obstrect entered in Block 20, If different from Report) 8. SUPPLEMENTARY NOTES 5. KEY WORDS (Continue on reverse side if necessary and identify by block number) Bioceramics Maxillofacial Tric Ceramic Implants Avulsive Wounds Calc Biomaterials Porous Ceramics Calc Prosthetic Materials Biodegradable Ceramics Implant Materials Bioresorable Ceramics 6. ADSTRACT (Continue on reverse other N necessary and identify by block number) (n Elocer Mices | 1977 |
| FORT DETTICK, Frederick, Maryland 21/01-5012 13 13 MONITORING AGENCY NAME & ADDRESS(II different from Controlling Office) 15. SECUI 14. MONITORING AGENCY NAME & ADDRESS(II different from Controlling Office) 15. SECUI 15. DISTRIBUTION STATEMENT (of the Report) 18. DEC Approved for public release; distribution unlimited. 7. DISTRIBUTION STATEMENT (of the obstract entered in Block 20, II different from Report) 8. SUPPLEMENTARY NOTES 9. KEY WORDS (Continue on reverse side II necessary and identify by block number) Bioceramics Maxillofacial Tric Ceramic Implants Avulsive Wounds Biomaterials Porous Ceramics Calc Prosthetic Materials Biologradable Ceramics 10 FOR CHARMICS (Continue on reverse other N messence) 0. ABETRACT (Continue on reverse side II necessary and identify by block number) 0. ADSTRIBUTION STATEMENT (of the obstract entered in Block 20, II different from Report) | R OF PAGES |
| MONITORING AGENCY HAME & ADDRESSIN BUILDEN HOL CONDUCTING CITED Uncla Ise. DEC. Uncla Ise. DEC. SCHE Approved for public release; distribution unlimited. Approved for public release; distribution unlimited. DISTRIBUTION STATEMENT (of the obstract entered in Black 20, if different from Report) DISTRIBUTION STATEMENT (of the obstract entered in Black 20, if different from Report) S. SUPPLEMENTARY NOTES SupplementARY NOTES Maxillofacial Tric Ceramic Implants Avulsive Wounds Calc Biomaterials Porous Ceramics Calc Prosthetic Materials Biodegradable Ceramics Implant Materials Biodegradable Ceramics ABSTRACT (Continue on reverse of M measurement and black for mumber) // Fioceramics | NTV CLASS (of this report) |
| DISTRIBUTION STATEMENT (of the Report) Approved for public release; distribution unlimited. DISTRIBUTION STATEMENT (of the obstract entered in Block 20, if different from Report) DISTRIBUTION STATEMENT (of the obstract entered in Block 20, if different from Report) S. SUPPLEMENTARY NOTES Supp | scified |
| 18. DECISION SUPPLEMENTARY NOTES KEY WORDS (Continue on reverse side if necessary and identify by block number) Bioceramics Maxillofacial Tric Ceramic Implants Avulsive Wounds Calc Biomaterials Porous Ceramics Calc Prosthetic Materials Biodegradable Ceramics Implant Materials Biodegradable Ceramics ABSTRACT (Continue on reverse side M messency and identify by block number) // Froceramics | 5511120 |
| Approved for public release; distribution unlimited. Approved for public release; distribution unlimited. DISTRIBUTION STATEMENT (of the obstract entered in Block 20, if different from Report) DISTRIBUTION STATEMENT (of the obstract entered in Block 20, if different from Report) SUPPLEMENTARY NOTES KEY WORDS (Continue on reverse eide if necessary and identify by block number) Bioceramics Maxillofacial Tric Ceramic Implants Avulsive Wounds Calc Biomaterials Porous Ceramics Calc Prosthetic Materials Biodegradable Ceramics Implant Materials Bioresorable Ceramics ABSTRACT (Continue on reverse eide M messenary and identify by block number) // Froceramics | ASSIFICATION/DOWNGRADING |
| SUPPLEMENTARY NOTES KEY WORDS (Continue on reverse elde II necessary and identify by block number) Bioceramics Maxillofacial Tric Ceramic Implants Avulsive Wounds Calc Biomaterials Porous Ceramics Calc Prosthetic Materials Biodegradable Ceramics Implant Materials Bioresorable Ceramics ABSTRACT (Continue on reverse odd M necessary and identify by block number) // Flocers Mics | |
| 9. KEY WORDS (Continue on reverse elde II necessary and identify by block number) Bioceramics Maxillofacial Tric Ceramic Implants Avulsive Wounds Calc Biomaterials Porous Ceramics Calc Prosthetic Materials Biodegradable Ceramics Implant Materials Bioresorable Ceramics 4. ABSTRACT (Continue on reverse other M necessary and identify by block number) Implant States | |
| B. KEY WORDS (Continue on reverse elde if necessary and identify by block number) Bioceramics (Continue on reverse elde if necessary and identify by block number) Bioceramics Maxillofacial Tric Ceramic Implants Avulsive Wounds Calc Biomaterials Porous Ceramics Calc Prosthetic Materials Biodegradable Ceramics Calc Implant Materials Bioresorable Ceramics Calc ABSTRACT (Continue on reverse oth M necessary and identify by block number) In Flocers Mics | |
| Bioceramics Maxillotacial Iric Ceramic Implants Avulsive Wounds Calc Biomaterials Porous Ceramics Calc Prosthetic Materials Biodegradable Ceramics Calc Implant Materials Bioresorable Ceramics Calc ADSTRACT (Continue on reverse oth M necessary and identify by block number) In Flocera mics | |
| Biomaterials Avuisive wounds Calc Biomaterials Porous Ceramics Calc Prosthetic Materials Biodegradable Ceramics Calc Implant Materials Bioresorable Ceramics Calc ABSTRACT (Continue on reverse other M necessary and identify by block number) In Flocers Mics | alcium Phosphate |
| Prosthetic Materials Biodegradable Ceramics Implant Materials Bioresorable Ceramics ABSTRACT (Continue on reverse other M necessary and identify by block number) in Flocers Mics | ium Athonhosphates |
| Implant Materials Bioresorable Ceramics ABSTRACT (Continue on reverse oth M necessary out identify by block number) in Figure Mics | ium ornophosphare |
| ABSTRACT (Continue on reverse older H necessary and identify by block number) in Flocer Mics | |
| in Floceramics | |
| | |
| Research studies were continued to further a | our understanding of |
| the in vivo behavior of resorbable calcium phosphate cer | umics for use in the |
| management of hard tissue avulsive wounds and orofacial | fractures. |
| | |

ور میں اور ان میں اور ان

Ó

11

SECURITY CLASSIFICATION OF THIS PAGE (Then Date Entered)

SECURITY CLASSIFICATION OF THIS PAGE(When Date Entered)

Material processing studies were conducted to develop porous tricalcium phosphate materials of different stoichiometry. These two portions of the study were to further understanding of the basic question: Is the optimal material for bone ingrowth and biodegradation going to be produced by alterations in stoichiometry or alterations in pore structure within the material of the given stoichiometry?

Numerous tricalcium phosphate powders were produced having controlled calcium to phosphate ratios. Specifically, three powders were prepared using the standard technique of modifying composition of tribasic calcium phosphate powders by the addition of phosphoric acid. After three powders of various composition were made at Battelle, the powders were millblended and submitted for verification analysis. Materials were then fired and analyzed by X-ray defraction to determine the crystalline phases that might be present in the finished implants. The results of the study indicated that preparation of a single phase variable composition material does not appear possible using standard methods even though beta phase tricalcium phosphate will be the predominant phase in all materials, secondary phases of monetite or hydroxyapatite were always found depending upon what border of the compositional range the compound fell. Consequently, these three different materials were not developed further. It was recommended that pore structure conformation be studied.

SECURITY CLASSIFICATION OF THIS PAGE(When Date Entered)

ABSTRACT

This report summarizes results of continued studies for further developing and understanding the <u>in vivo</u> behavior of resorbable calcium phosphate for use in the management of hard tissue avulsive wounds and orofacial fractures.

Specific studies have been devoted to the preparation and evaluation of tricalcium phosphates having various altered stoichiometries.

This study concluded that a single phase variable composition material could not be produced. Therefore, it was suggested that resorption rate alteration be attempted by varying the pore distribution and configuration of the material.

| Í | Access | ion For | r / | | | | | | |
|--------|--------------|---------|--|--|--|--|--|--|--|
| Ţ | NTIS | GRA&I | | | | | | | |
| | DTIC 1 | LAB | | | | | | | |
| | Unanno | punced | | | | | | | |
| | Justli | ticatio | n | | | | | | |
| | ······ | | | | | | | | |
| | By | | | | | | | | |
| | Distr | ibution | / | | | | | | |
| | Avai | labilit | y Codes | | | | | | |
| | Avail and/or | | | | | | | | |
| BRIC | Dist | Spec | ial | | | | | | |
| | | | l | | | | | | |
| # BOPY | 101 | 4 | | | | | | | |
| | 171 | } | } | | | | | | |
| | | Luna | Construction of the local division of the lo | | | | | | |

SUMMARY

Research studies were continued to further our understanding of the $\underline{in \ vivo}$ behavior of resorbable calcium phosphate ceramics for use in the management of hard tissue avulsive wounds and orofacial fractures.

Stored States and States (States and)

Material processing studies were conducted to develop porous tricalcium phosphate materials of different stoichiometry. These two portions of the study were to further understanding of the basic question: Is the optimal material for bone ingrowth and biodegradation going to be produced by alterations in stoichiometry or alterations in pore structure within the material of the given stoichiometry?

Numerous tricalcium phosphate powders were produced having controlled calcium to phosphate ratios. Specifically, three powders were prepared using the standard technique of modifying composition of tribasic calcium phosphate powders by the addition of phosphoric acid. After three powders of various composition were made at Battelle, the powders were millblended and submitted for verification analysis. Materials were then fired and analyzed by X-ray defraction to determine the crystalline phases that might be present in the finished implants. The results of the study indicated that preparation of a single phase variable composition material does not appear possible using standard methods even though beta phase tricalcium phosphate will be the predominant phase in all materials, secondary phases of monetite or hydroxyapatite were always found depending upon what border of the compositional range the compound fell. Consequently, these three different materials were not developed further. It was recommended that pore structure conformation be studied.

FOREWORD

This study has been conducted at Battelle's Columbus Laboratories utilizing the talents and resources of the Ceramic Materials Section and the Bioengineering/Health Sciences Section. This is an Annual Progress Report under Contract No. DADA17-69-C-9118, "Management of Hard Tissue Avulsive Wounds and Management of Orofacial Fractures". The Principal Investigator for this research was Mr. Larry G. McCoy.

We would like to acknowledge the valuable assistance of Mr. Roger K. Beal for his excellent work in preparation of the porous implant materials. Citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement or approval of the products or services of these organizations.

TABLE OF CONTENTS

Real Property

ñ

ń

1. a. .

| | <u></u> |
|--|---------|
| BACKGROUND, PROBLEM AND APPROACH | 1 |
| MATERIALS, METHODS AND RESULTS | 3 |
| Variable Stoichiometry Materials Development | 3 |
| CONCLUSIONS | 6 |
| REFERENCES | 7 |
| | |

List of Figures

| Figure 1. | System | Ca0-2Ca0.P205 | C : | = CaO, | Ρ : | = P ₂ O ₅ | • | • | • | | • | • | • | • | • | 1 | 4 |
|-----------|--------|---------------|------------|--------|-----|---------------------------------|---|---|---|--|---|---|---|---|---|---|---|
|-----------|--------|---------------|------------|--------|-----|---------------------------------|---|---|---|--|---|---|---|---|---|---|---|

NOTE STREET OF

e Liberto

N. 17-14-14

Page

BACKGROUND, PROBLEM AND APPROACH

Historically, various techniques have been employed for the repair or treatment of osseous diseases, defects, and wounds. Autogeneous bone grafting remains the most satisfactory approach but is not without the disadvantages associated with double surgeries and the limitations imposed on the repair of massive osseous defects.

Since April, 1970, Battelle's Columbus Laboratories has been conducting research under contract with the Dental Research Division, U.S. Army Medical Research and Development Command, on the development of resorbable ceramics for potential application in the repair of hard tissue avulsive wounds. The basic materials have been calcium phosphates. These materials were selected because they contain two of the essential elements of the natural bone mineral phase, calcium hydroxyapatite.

<u>In vivo</u> studies were conducted initially at U.S. Army Institute of Dental Research (USAIDR), using the sintered porous materials and slurries prepared at Battelle from tricalcium phosphate $Ca_3(PO_4)_2$ and other calcium orthophosphate powders CaHPO₄ and Ca(H₂PO₄)₂, to evaluate the potential use of calcium phosphates to both facilitate repair of bone defects and to determine the best material for future exploration⁽¹⁻³⁾. The implant studies indicated that calcium phosphates consisting essentially of the mineral phases Ca(PO₃)₂, Ca₃(PO₄)₂, and CaHPO₄ are well tolerated by the tissue, appear to be nontoxic, are resorbable, and permit rapid invasion of new bone.

Of the various porous calcium phosphate materials investigated, tricalcium phosphate, $Ca_3(PO_4)_2$, was selected for continued development and evaluation since it was easy to fabricate and was found to be both biocompatible and resorbable. Emphasis has been directed toward producing low-density porous materials consisting of single-phase tricalcium phosphate⁽⁴⁻⁷⁾.

Although previous implant studies at USAIDR have demonstrated that porous tricalcium phosphate is biocompatible, resorbable, and promotes or permits rapid ingrowth of new bone, histological evidence indicated persistence of a residual ceramic structure as long as 1 year after implantation. This structure appeared to be composed of an isomorphic distribution of small encapsulated ceramic particles. The presence of this residue would be expected to retard complete remodeling of the bone and the attendant strength development.

As a result of this problem, the primary emphasis of continued studies was directed toward the development of porous materials having improved (increased) resorption rates. This objective may be achieved either by changes in structure or chemistry of the ceramic implant material.

To provide basic resorption rate data on the <u>in vivo</u> behavior of the tricalcium phosphate bioresorbable ceramics, implant studies were initiated in 1975 at BCL using the rabbit calvarium model(8). Historic samples of tricalcium phosphate were implanted as a control and samples of two new materials were implanted for comparative observation. These new materials were prepared using the improved processing techniques derived in previous materials development studies and represented significant improvements in the structural characteristics of porous tricalcium phosphate. The characterization of the materials involved and the results of the <u>in vivo</u> studies were the subject of the Fifth Annual Report(8).

These results indicated that the improved material exhibited significant increases in resorption rate. In fact, the material resorbed so rapidly that after the ninth month the implant appeared to be granulated and was invaded with connective tissue. This result does not imply lack of biocompatibility but does suggest that such rapid degradation can be deleterious in stress-bearing situations. It is not known whether the enhanced resorptivity resulted from achieving a Ca/P ratio closer to the theoretical for tricalcium phosphate or from the improvements in the structural characteristics of the material.

The objective of this years effort was to prepare materials with minor variations in chemical composition so that the resorption rate of porous tricalcium phosphate materials which have identical pore structures could be ascertained. For this study, it was necessary to prepare new tricalcium phosphate powders having controlled Ca/P ratios. However, to achieve a structurally sound and single phase ceramic, the composition of the new powders must lie within a very narrow β -C₃P (beta tricalcium phosphate) solid solution region.

MATERIALS, METHODS AND RESULTS

Variable Stoichiometry Materials Development

To discern the effect of chemistry, it was sought to develop a tricalcium phosphate having variable stoichiometry. This was based on the observation of the P_2O_5 -CaO phase diagram as proposed by Welch and Gutt, which showed a solid solution region at 800°C with a Ca/P ratio of 1.788 to 1.941 for tricalcium phosphate.

For this study, it was necessary to prepare new tricalcium phosphate powders having controlled Ca/P ratios. To achieve a structurally sound and single phase ceramic, the composition of the new powders must lie within the β -C₃P (beta tricalcium phosphate) solid solution region shown in Figure 1. The composition range of the solid solution is quite narrow; the phosphorous content ranges from 20.0 to 20.8 weight percent (45.8 percent as P₂O₅).

Three powders having the compositions designated A, B, and C in Figure 2 were prepared by the standard technique of modifying the composition of tribasic calcium phosphate, $Ca_{10}(OH)_2(PO_4)_6$ by the addition of phosphoric acid. The nature of this method has necessitated reliance on an iterative formulation/analysis/adjustment procedure for producing precise compositions. For an analysis standard, a stoichiometric tricalcium phosphate composition was prepared using a chelometric standard grade of calcium carbonate (100.0 percent \pm 0.05 CaCO₃)* dissolved in the appropriate concentration of a certified phosphoric acid (85 percent \pm 0.05 H₃PO₄).

The end member powder compositions A and C were prepared first and were chemically analyzed for total Ca and P contents. Although the absolute values reported for both the Ca and P contents were below the targeted values, when the data were normalized on the basis of the known Ca/P ratios of the analytical standard, the results agreed quite closely with the targeted Ca/P ratio. Powders A and C were then mill blended in equal proportions to prepare

*Fisher Scientific, Inc., Pittsburgh, Pennsylvania.



CaO-P2Os

FIGURE 1. SYSTEM CaO-2CaO·P₂O₅ C = CaO, P = P_2O_5

A STATE OF A

the intermediate B composition and samples of all three were submitted for verification analysis. The results of this second analysis were not consistent with the first. As a further check, a third set of samples was analyzed. After normalization on the basis of the known Ca/P ratio of the standard, the results somewhat verified the second analysis (i.e., all compositions were approximately 1 percent calcium rich). However, there was sufficient variation between the results (i.e., approximately 25 percent of the solid solution range) that significant doubt was generated as to the validity of the analysis procedures and/or the ability to produce sufficiently homogeneous powders by the standard procedure.

Although the validity of the above results was uncertain, standard procedures were continued toward the fabrication of porous implant specimens. After the firing, samples of each material were analyzed by x-ray diffraction to determine the crystalline phases that might be present in the finished implant.

Although β -Ca₃(PO₄) was the predominant phase in all the materials, there were secondary phases of either monetite (CaHPO₄) or hydroxyapatite Ca₁₀(OH)₂(PO₄)₆, depending on what border of the composition range the composition fell. These results suggest that it is not possible to produce a nonstoichiometric tricalcium phosphate with typical low temperature sintering processes. It may be possible to quench melts of CaO and P₂O₅ of the appropriate Ca/P ratio to achieve tricalcium phosphate of variable stoichiometry as is normally the procedure for determining phase diagrams. However, this is not a practical procedure for producing sinterable powders.

Since the preparation of single phase variable composition material does not appear possible, continuation of the chemistry versus resorption characteristics study is obviated. Although it is feasible to conduct implant studies with the present two-phase materials, the presence of these second phases would only confuse the interpretation of whether any observed effects were due to the tricalcium phosphate or the secondary phases. Consequently, further preparation of these materials was terminated and no implant studies were initiated.

CONCLUSIONS

From this study it appears that preparation of single phase variable composition is not possible. Even though two phase materials could be produced they would not serve the purpose of the study, to observe the effect of composition upon resorption rate in <u>vivo</u>. Consequently, these studies were terminated. It is recognized that the effect of pore size now be explored as a method of altering resorption rate.

REFERENCES

- Bhaskar, S. N., Cutright, D. E., Knapp, M. J., Beasley, J. D., and Perez, B., "Tissue Reactions to Intrabone Ceramic Implants", <u>Oral</u> <u>Surg., Oral Med., Oral Path.</u>, <u>31</u>:282-289 (February, 1971).
- (2) Bhaskar, S. N., Brady, J. M., Getter, L., Grower, M. F., and Driskell, T. D., "Biodegradable Ceramic Implants in Bone (Electron and Light Microscopic Analysis): <u>Oral Surg., Oral Med., Oral Path.</u>, <u>32</u>:336-346 (August, 1971).
- (3) Getter, L., Bhaskar, S. N., Cutright, D. E., Bienvenido, P., Brady, J. M., Driskell, T. D., O'Hara, M. J., "Three Biodegradable Calcium Phosphate Slurry Implants in Bone", J. of Oral Surgery, <u>30</u>:263-268 (April, 1972).
- Driskell, T. D., O'Hara, M. J., and Greene, G. W., Jr., D.D.S., "Management of Hard Tissue Avulsive Wounds and Management of Orofacial Fractures", Report No. 1, Contract No. DADA17-69-C-9118, February 1, 1971.
- (5) Driskell, T. D., O'Hara, M. J., and Grode, G. A., "Management of Hard Tissue Avulsive Wounds and Management of Orofacial Fractures", Report No. 2, Contract No. DADA17-69-C-9118, October, 1971.
- Driskell, T. D., O'Hara, M. J., Niesz, D. E., and Grode, G. A., "Management of Hard Tissue Avulsive Wounds and Management of Orofacial Fractures", Report No. 3, Contract No. DADA17-69-C-9118, October, 1972.
- McCoy, L. G., Hassler, C. R., Wright, T. R., Niesz, D. E., "Management of Hard Tissue Avulsive Wounds and Management of Orofacial Fractures", Report No. 4, Contract No. DADA17-69-C-9118, July, 1974.
- (8) McCoy, L. G., Hassler, C. R., and Niesz, D. E., "Management of Hard Tissue Avulsive Wounds and Management of Orofacial Fractures", Report No. 5, Contract No. DADA17-69-C-9118, July, 1976.

4 copies

A CARACTER

Sec. Sec.

12 copies

1 copy

1 copy

Commander U.S. Army Medical Research and Development Command ATTN: (SGRD-RMS) Frederick, MD 21701-5012

Administrator Defense Technical Information Center ATTN: DTIC-DDA Cameron Station Alexandria, Virginia 22304-6145

Commandant Academy of Health Sciences, U.S. Army ATTN: AHS-CDM Fort Sam Houston, Texas 78234-6100

Dean School of Medicine Uniformed Services University of the Health Sciences 4301 Jones Bridge Road Bethesda, Maryland 20814-4799

8

1. 1.

7.8562.8782

BNBUXE LNEWINIANDE LY DEDRODIABU

DTIC

9-85

FILMED